SEARCH

SEARCH BY CITATION

Keywords:

  • central nervous system;
  • chronic fatigue syndrome;
  • depression;
  • hypothalamic dysfunction;
  • neurasthenia;
  • stress.

Abstract

  1. Top of page
  2. Abstract
  3. Historical background and origins
  4. Clinical picture and epidemiology
  5. CFS and psychiatric disorders
  6. Is CFS a post-infectious condition?
  7. Immunological findings
  8. Influence of stress
  9. Conclusion
  10. References

Abstract. Evengård B, Schacterle RS, Komaroff AL (Karolinska Institute at Huddinge University Hospital, Huddinge, Sweden; and Brigham and Women’s Hospital, Harvard Medical School, Boston, USA). Chronic fatigue syndrome: new insights and old ignorance. J Intern Med 1999; 246: 455–469.

Chronic fatigue syndrome (CFS) is a condition characterized by impairment of neurocognitive functions and quality of sleep and of somatic symptoms such as recurrent sore throat, muscle aches, arthralgias, headache, and postexertional malaise. A majority of patients describe an infectious onset but the link between infections and CFS remains uncertain. Findings show an activation of the immune system, abberations in several hypothalamic-pituitary axes and involvement of other parts of the central nervous system. The origin is bound to be complex and it may well be that the solution will come together with a more generally altered view about mind–body dualism, and the concept of illness and disease.


Historical background and origins

  1. Top of page
  2. Abstract
  3. Historical background and origins
  4. Clinical picture and epidemiology
  5. CFS and psychiatric disorders
  6. Is CFS a post-infectious condition?
  7. Immunological findings
  8. Influence of stress
  9. Conclusion
  10. References

The first descriptions in the medical literature of the illness now known as chronic fatigue syndrome (CFS) probably appeared during the middle of the 19th century, although some argue that similar illnesses were described as early as the 17th century [1]. In the 19th century, an American neurologist named Charles Beard popularized the diagnosis of ‘neurasthenia’, and his descriptions of the illness bear a strong resemblance to what we call CFS today [2]. Neurasthenia was one of the most frequently diagnosed conditions in medical practice during the late 19th century [34]. However, the increasing sophistication of psychiatric diagnoses (such as the emergence of obsessive–compulsive disorder, anxiety, neurosis, and hysteria) [5] was accompanied by a decreased frequency of the diagnosis of neurasthenia. The outbreak at the Royal Free Hospital in 1955 [67] was retrospectively regarded as a case of mass hysteria by McEvedy & Beard [8], but their conclusion has caused many objections and has been rejected [9]. Thus, the issue of the cause of CFS has been one of controversy.

Since that diagnostic label fell out of favour in the early 20th century, other illness labels have been applied to similar conditions such as epidemic neuromyasthenia, myalgic encephalomyelitis, Icelandic disease, Royal Free disease, post-viral fatigue syndrome, and chronic mononucleosis.

Recently the Royal Colleges of Physicians, Psychiatrists, and General Practitioners in the United Kingdom recommended dropping the diagnostic term myalgic encephalomyelitis or ME, widely used in the United Kingdom in recent decades, because there is, so far, no recognized pathology in muscles and in the central nervous system – as is implied by the term ME. Instead, the term chronic fatigue syndrome was recommended, as defined by the United States’ Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) [10] and is today the most commonly used name. The current case definition is summarized in Figure 1. This definition stresses the appearance of somatic symptoms. No objective measurements are used – only symptoms reported by the patient. With the 1994 definition, consensus was reached on which tests would be necessary before making the diagnosis: complete blood count, erythrocyte sedimentation rate, alanine aminotransferase, total protein, albumin, globulin, alkaline phosphatase, calcium, phosphate, glucose, blood urea nitrogen, electrolytes, creatinine, thyroid stimulating hormone and urinalysis. Less common, and more expensive, testing such as lymphocyte phenotyping and neuroimaging studies are not necessary, although they have been used in research studies to help understand the biology of CFS.

image

Figure 1. revised [1994] case definition of chronic fatigue syndrome and idiopathic chronic fatigue: an algorithm for evaluation.

Download figure to PowerPoint

Over the past decade, a good deal has been learned about the biological underpinnings of this illness, although its cause remains unknown.

Clinical picture and epidemiology

  1. Top of page
  2. Abstract
  3. Historical background and origins
  4. Clinical picture and epidemiology
  5. CFS and psychiatric disorders
  6. Is CFS a post-infectious condition?
  7. Immunological findings
  8. Influence of stress
  9. Conclusion
  10. References

Although fatigue is a human experience, and although many people report experiencing chronic fatigue intermittently, CFS is quite different and quite unusual. Fatigue is a very common symptom in community-wide surveys performed in different countries in the Western world [11]. In the Swedish study from Lundby [12] the lifetime prevalence of chronic fatigue (defined similarly to neurasthenia) was 33% for women and 21% for men. Whether there has been a real increase in fatigue prevalence has not been established, but in a study from 1960 only 9% of out-patients reported fatigue as a principal complaint, whilst some 30 years later the prevalence at two American medical clinics was 33% [1314]. An editorial [15] underscored the substantial impact of ‘minor’ illness symptoms, such as fatigue, on lost productivity and revenue. A large, population-based study in the United Kingdom found that 30% of women and 19% of men reported experiencing a persistent fatigue for at least the past month [16].

CFS, on the other hand, is less common and varies with the case definition used and the population under study. Studies of community-based populations, irrespective of whether people have sought medical care for any condition (including fatigue), in the U.S. have come to similar conclusions. In a community-based prospective study in the greater Seattle, Washington area [17] questionnaires were sent by mail to 4000 people, and follow-up testing was performed on potential chronic fatigue cases. The estimated prevalence of CFS was found to be 0.07–0.2%, whilst the prevalence of chronic fatigue alone was much higher at 1.8–6.3%.

The prevalence of CFS in populations seeking medical care is much higher than in community-based samples. In one U.S. study, the prevalence was found to be about 1% amongst patients seeking medical care for any reason (not just seeking care for fatigue). In a primary care practice study in the U.K., Wessely et al. [18] found the point prevalence of chronic fatigue was 11.3%, falling to 4.1% if patients with comorbid psychological disorders were excluded. The point prevalence of CFS was 2.6%, falling to 0.5% if patients with comorbid psychological disorders were excluded.

Whether CFS shares overlapping symptoms with other syndromes which include fatigue as a symptom (e.g. fibromyalgia and multiple chemical sensitivities) has not been well-characterized. One study [19], however, reported significant demographic and symptom overlap.

In any illness defined by a group of symptoms, two questions arise: do the patients with the illness in fact report the symptoms that investigators say they should, and do those symptoms distinguish patients with CFS from patients with other fatiguing illnesses. A recent study from the CDC reports that when a very large population of individuals was asked about a variety of chronic symptoms, there did indeed emerge a group of individuals who spontaneously described the symptoms of CFS [20]. Another study compared the reporting of CFS symptoms by patients with CFS, by patients with other fatiguing illnesses, and by healthy control subjects. The symptoms of CFS, but not other ‘control’ symptoms, were reported much more frequently by patients with CFS than by patients with other diseases that produce chronic fatigue, such as multiple sclerosis and major depression, and by healthy subjects [21].

Gender

Most reports from hospitals or specialty practices that care for patients with CFS have found a higher fraction of women than men: about 70% women. This female predominance must be placed in context: about 60% of visits to doctors for all reasons are by women, and many diseases that produce fatigue have a predominance of females that is considerably greater – such as multiple sclerosis, systemic lupus erythematosus.

Moreover, when the prevalence of CFS is studied in the population at large, irrespective of whether they have sought medical care, it is almost as probable that men will meet the criteria for CFS as women [2223].

Socio-economic level

There are also differences in the socio-economic levels of patients with CFS who seek medical care, versus those identified in community surveys. As with female gender, patients who seek medical care for CFS may be of slightly higher socio-economic level, and are less often non-Caucasian. However, in community-based studies in the US, there appears to be a higher prevalence of CFS in people of lower socio-economic groups, and in African-Americans and Latino populations [2223].

CFS and psychiatric disorders

  1. Top of page
  2. Abstract
  3. Historical background and origins
  4. Clinical picture and epidemiology
  5. CFS and psychiatric disorders
  6. Is CFS a post-infectious condition?
  7. Immunological findings
  8. Influence of stress
  9. Conclusion
  10. References

Some of the symptoms of CFS are commonly seen in patients with nonpsychotic psychiatric disorders, including fatigue, sleep disturbance and cognitive difficulties. For this reason, and because no objective diagnostic test for CFS has been found, some physicians believe that CFS is a psychiatric disorder. Whereas this belief was extremely common a decade ago, it is less common today, as more research has been conducted, and as physicians gain more experience in caring for these patients.

The question of whether the diagnosis of CFS should be applied in patients with comorbid psychiatric disorders has been hotly debated. In the current case definition, bipolar disorder, ‘melancholic depression’, and several comorbid psychotic disorders disallow the diagnosis of CFS, whereas major unipolar depression, dysthymia and various anxiety disorders do not. However, it is recommended that investigators segregate patients with and without comorbid psychiatric illness from other patients in analysing data, to be sure that the variables being measured do not reflect confounding by these psychiatric disorders.

The prevalence of ‘allowable’ psychiatric disorders amongst patients with CFS is also an area of controversy [924–28]. Many investigators have tried to distinguish the presence of psychiatric disorders that were present before the onset of CFS, versus those that occurred after the onset of CFS and could be viewed as ‘reactive’ psychiatric illness in response to a chronic illness. Although there is some variability amongst studies, the following summary is a fair reflection of the literature: it is more probable that patients with CFS will have experienced at least one episode of major depression in the years before the onset of CFS than the typical member of the population; nevertheless, the majority of patients with CFS do not have such a history. Nearly half of patients with CFS develop depression in the years after the onset of CFS, but again a sizeable fraction do not. The frequency of panic disorder may also be higher in patients with CFS, both before and after the onset of CFS, but the majority of patients with CFS have never experienced that disorder.

One important distinction between major depression and CFS is that guilt, lack of self-esteem, and self-blame – core features of major depression – are much less frequent in patients with CFS [29]. Instead of being apathetic and hopeless, as are most patients with major depression, patients with CFS are often frustrated, angry and eager to try anything to make them healthy.

One indirect indication that CFS is different from major depression is that – in contrast to patients with major depression – patients with CFS have very different scores on the widely used instrument that measures self-reported functional status, the Medical Outcomes Survey 36-Item Short-Form Health Survey (SF-36). On this instrument, CFS patients – in comparison to patients with major depression – showed significantly greater impairment in physical functioning, role limitations due to physical health problems, bodily pain, general health perceptions, vitality, and social functioning, and significantly higher scores for mental health and role limitations due to emotional health problems [21].

Several objective tests also seem to distinguish patients with CFS from those with major depression. Demitrack et al. [30] found that the up-regulation of the hypothalamic-pituitary–adrenal axis that is often present in patients with major depression was not seen in patients with CFS: indeed, patients with CFS had a down-regulation of the axis, with a central underproduction of corticotropin-releasing hormone (CRH) that leads ultimately to a slight hypocortisolism. Also, patients with CFS have an opposite response to patients with major depression in prolactin release after central stimulation [31–33]. Finally, in a comparison of SPECT imaging of the brain, the midcerebral uptake index (an objective measure of global radionuclide uptake) was significantly lower in CFS patients than in patients with major depression or healthy controls, and was similar to that seen in patients with AIDS encephalopathy [34].

Is CFS a post-infectious condition?

  1. Top of page
  2. Abstract
  3. Historical background and origins
  4. Clinical picture and epidemiology
  5. CFS and psychiatric disorders
  6. Is CFS a post-infectious condition?
  7. Immunological findings
  8. Influence of stress
  9. Conclusion
  10. References

Many patients refer to an infectious type of onset with a flu-like illness. In the beginning of this century several authors pointed out that neurasthenia could follow infections such as influenza [35–38]. Since then different microorganisms have been postulated to play a role in the pathogenesis of CFS. However, the link between infections and CFS remains uncertain.

CFS following acute infections

There are a few reported cases in which CFS has followed in the wake of a well-documented acute infection – as contrasted to the nonspecific ‘infectious-like’ symptoms that many patients report at the onset of the illness. CFS can follow acute infectious mononucleosis, which is typically caused by Epstein–Barr virus, properly diagnosed and treated Lyme disease [39–41], and Q fever [42]. Whilst these case reports provide strong evidence that CFS occasionally can be triggered by an acute infection with an agent (viral or bacterial) that has the capacity to produce a chronic infection, it is unclear what they may tell us about the aetiology of most cases of CFS. The role of these infectious agents in causing the ongoing, chronic illness remains unclear.

Acute infection with other infectious agents can be followed by CFS. These agents include other bacteria (Brucella) , rickettsial organisms and protozoal infection (toxoplasmosis and giardiasis) [43].

Apparent epidemics of CFS

Many apparent epidemics of an illness much like CFS have been reported in the medical literature of the past 70 years. The outbreaks have occurred all over the world [4445]. Some have occurred in hospitals – at the Los Angeles County Hospital in 1934 [46] and at London’s Royal Free Hospital in 1955 [67]. One of the latest reported outbreaks was in the Lake Tahoe/Incline Village area of Nevada in the late 1980s [47–49].

Reactivation of latent infections and CFS

The most recent wave of interest in CFS began in the mid-1980s with reports that antibody profiles indicated a chronic reactivation of latent infection with Epstein–Barr virus (EBV) [5051]. Whilst subsequent studies have largely found similar evidence of reactivation of EBV, the current general consensus is that rather than indicating a primary role for EBV in producing the symptoms of CFS, this more probably reflects a state of chronic immune dysregulation.

Human herpesvirus-6 (HHV-6) is activated more often in patients with CFS [4952–54]. HHV-6 is an attractive potential pathogenic agent in CFS, since it has a remarkably wide tissue tropism: several peripheral mononuclear white blood cells, respiratory and intestinal epithelial cells, fibroblasts, and central nervous system cells. Moreover, it is now clear that HHV-6 can produce clinical encephalitis and is associated with demyelinating diseases in immunosuppressed individuals and with multiple sclerosis in immunocompetent individuals [55–57]. However, like EBV, infection with HHV-6 is ubiquitous, and it is possible that the reactivation of HHV-6 in patients with CFS is a secondary event, reflecting immune dysregulation. There is as yet no compelling evidence that HHV-6 produces the pathology that leads to the symptoms of CFS.

Retroviruses have been reported to be involved [58], although this has not been confirmed [59]. Another type of virus which has drawn a lot of attention is the enterovirus group [60–62] because clinical symptoms in CFS are similar to those found in enterovirus infections. So far, there is no clear evidence for an active involvement in studies based on either serology or muscle biopsies [6063–66]

Borna disease virus (BDV) is a newly classified neurotropic, negative-stranded RNA virus that infects warm-blooded animals causing profound neurological abnormalities [6768]. The infection results either in a meningo-encephalitis with neurological symptoms or in a mild persistent infection with cognitive and mood disorders in affected animals. Whether BDV naturally infects humans to cause neuropsychiatric disease remains controversial, however, there are now reports suggesting an involvement of BDV in CFS [6970]. This has not been the finding of others [70a] leaving unproven a BDV correlation with CFS.

Indirect evidence of a chronic viral infection in CFS

Patients with CFS may have an abnormality in an antiviral lymphocyte enzyme system called the 2–5 A pathway: the pathway appears to be chronically activated in patients with CFS [7172]. A case-control study, involving more than 700 patients from two different geographical areas, found a much higher frequency of atypical lymphocytes in patients with CFS than in healthy control subjects [73]. These studies indirectly suggest the presence of a chronic viral infection, but are far from constituting proof of such an infection.

Thus, there are findings from blood testing consistent with involvement of an infectious agent. The exact nature of this involvement (e.g. a triggering event) remains an open question. So far, no microbes have been isolated and correlated to symptoms.

Immunological findings

  1. Top of page
  2. Abstract
  3. Historical background and origins
  4. Clinical picture and epidemiology
  5. CFS and psychiatric disorders
  6. Is CFS a post-infectious condition?
  7. Immunological findings
  8. Influence of stress
  9. Conclusion
  10. References

A growing number of immunological studies have been conducted, by different laboratories, on different groups of patients. Not all of the studies come to the same conclusions, although some common themes are emerging. One problem may be that, as the CDC criteria now used for diagnosis was established in 1994, after many of these studies were conducted, comparable patient populations may not have been studied.

Lymphocyte phenotyping studies

Landay and coworkers [74] reported a decreased percentage of CD8+/CD11b+ suppressor T cells and an increase in CD8+/CD11b-cytotoxic T cells. A marked activation in severely ill patients indicated by increased levels of CD38 and HLA-DR was also found. A decreased CD4+/CD8+ ratio has been reported as differing significantly from control groups [7576]. Also, a decrease in CD4+/CD45RA+ cells (naïve helper T cells) was reported in both studies and Straus’ group noticed a rise in memory cells (CD8+/CD45RO+). One study found an increased number of B cells [77]. Reports of the total number of natural killer (NK) cells have varied, as have reports of the fraction of NK cells bearing activation antigens

Lymphocyte functional studies

Perhaps the most robust immunological finding in patients with CFS is the depressed function of natural killer cells [78–83]. Although not specific for CFS, depressed NK cell function has been consistently seen. The clinical implications of this finding remain uncertain. NK cells are thought to play a central role in defending against viral infections.

Another reasonably consistent finding in patients with CFS is that T cell responses to mitogens and specific antigens are depressed [75768485]. Also, a depressed delayed-type hypersensitivity reaction has been described [85].

Serologic markers of immune activation

Other markers of immune activation also have been found: elevated levels of circulating immune complexes, and immunoglobulin G, and higher frequencies of various autoantibodies [7386]. It is not clear that these abnormalities have any relationship to the symptoms reported by patients with CFS [87].

An attractive but unproved hypothesis is that a state of chronic immune activation could lead to the production of cytokines that disrupt neurotransmitter function and result in the symptoms of CFS. Cytokines are a possible link between a possible infectious agent and CFS symptoms. Treatment with cytokines such as interleukin-1 (IL-1) can cause symptoms similar to those of CFS. Extensive studies searching for cytokines in serum, however, have not been conclusive. A recent publication shows increased levels of TGF-β in serum from patients compared to healthy controls and other patient comparison groups [88]. An increase in this cytokine was reported earlier by Chao et al. [89] who also described an increase of neopterin, a marker of macrophage activation. Increased serum levels of IL-6 and IL-1α also have been reported [9091]. When spontaneous or stimulated cytokine release was measured from peripheral cells of patients, spontaneous release of TNF-α and IL-6 was increased, whilst both spontaneous and stimulated release of IL-10 was suppressed [92].

It is well known that some female patients have symptoms correlating to their menstrual cycle. Cannon and coworkers [93] showed an abnormality in IL-1β secretion in patients that may be related to altered sensitivity to estradiol and progesterone. They also showed increased release of IL-1Ra and sIL-1RII by cells from patients suggesting a low-level activation of the immune system.

Additional evidence for activation of the immune system is the up-regulation of the 2–5 A synthetase/RNase L antiviral pathway, an enzyme produced in leucocytes and induced by interferon, found in patients [7172]. It leads to increased RNase levels and decreased cell metabolism.

Muscle abnormalities

As muscular symptoms are a substantial part of the syndrome, researchers have looked for pathophysiological explanations, but no underlying pathology in muscle tissue has been identified [94]. CFS patients show normal muscle physiology before and after exercise [95]. In this study, the degree of perceived exertion was significantly greater, in relation to the increase in heart rate, during exercise in CFS patients. This has also been shown by Lloyd et al. [96]. Perception of effort thus appears to be different in these patients.

Central nervous system abnormalities

Since many of the symptoms of CFS – fatigue, disrupted sleep, cognitive difficulties, pain – suggest involvement of the central nervous system (CNS), many investigators have looked for objective evidence of abnormalities. In our view, the evidence of CNS pathology is substantial.

Magnetic resonance imaging [MRI] demonstrates white matter abnormalities more often in patients with CFS than in healthy control subjects [4997]. Often, subcortical areas are involved, and sometimes deeper structures. No studies correlating tissue with MRI findings have been performed. Based on animal studies, such MRI abnormalities probably represent areas of inflammation and/or demyelination.

Single photon emission computed tomography [SPECT] abnormalities, indicating either defects in perfusion or CNS cellular function, have also been found more often in CFS than in healthy control subjects or patients with depression [3498]. Hypoperfusion of the brainstem has been reported [99], but technical objections to the evaluation of these findings have been raised [100]. Studies using these techniques in a normal population, as well as in other patient groups having impaired cognitive function, have not been widely conducted. Therefore, the optimal use of these techniques in CFS patients is unknown.

Autonomic nervous system testing – such as vertical challenge on a tilt-table – has demonstrated abnormalities of the sympathetic and parasympathetic systems [101102], and a picture like that seen in neurally mediated hypotension and orthostatic tachycardia. Physical deconditioning does not appear to explain the abnormalities, nor does a coexistent depression [102]. Studies are underway of treatments commonly used for neurally mediated hypotension – such as increasing salt intake, fludrocortisone, or beta-blockers.

Hypothalamic functional testing is abnormal in many patients with CFS. The stress axis has been studied most intensively, following the important report of Demitrack et al.[30], and is mentioned in more detail below. Disruption of both serotonergic and noradrenergic pathways also has been demonstrated in patients with CFS [32103104]. Not only have these objective abnormalities been demonstrated reproducibly by several laboratories, but they are also in patterns opposite to those seen in major depression. Many of the symptoms of CFS could result from such hypothalamic dysfunction.

Central and peripheral balance centre testing also has found abnormalities in patients with CFS [105106], although no treatment studies based on these observations have yet been conducted.

Formal testing of cognition has been used in an attempt to make objective measurements of the cognitive debilitation found in this condition. In this type of study it is important to start with well-characterized patient and control groups. It is also important to include depressed patients who do not have CFS, diagnosed according to the criteria in the DSM-IV, as cognitive deficits in CFS patients are often attributed to a secondary depression [107108]. Cognitive deficits have also been described in patients having an ongoing viral infection such as mononucleosis [109].

Recent results have pointed to a specific impairment of information processing in CFS patients [110]. Impairments in learning and memory were described in a subset of patients [111112]. When this patient group was compared with patients with multiple sclerosis and patients with depression, greater deficits were seen in the CFS patients in specific tests such as complex auditory information processing [113]. DeLuca et al.[114] concluded that impaired cognition in CFS cannot be explained solely by the presence of a psychiatric condition. When CFS patients were subgrouped into those reporting sudden versus gradual illness onset, a differentiation between groups emerged. The rate of concurrent psychiatric disease was significantly greater in the gradual onset group. Whilst both groups showed a significant reduction in information processing ability compared to controls, impairment in memory was more severe in patients with sudden onset, pointing to a need to stratify patients according to the type of onset [115]. Although methodologies may differ, some consistent findings have been reported in CFS patients such as impairments in complex information processing speed and efficiency [116].

Sleep laboratory studies in patients with CFS have variable results. Moldofsky [117] found the same specific pattern of disordered sleep physiology (an alpha rhythm disturbance within the nonrapid eye movement sleep) in patients CFS as he had earlier found in patients with the similar syndrome, fibromyalgia. Krupp found that the sleep disturbances in CFS were less specific, but were different from those seen in patients with MULTIPLE SCLEROSIS or in healthy control subjects [118]. Buchwald et al. found that sleep pathology in patients with CFS was unrelated to concomitant psychiatric diagnoses, and that treatment of frank sleep disorders never resolved the symptoms of CFS [119], indicating that the sleep pathology was secondary to, rather than a cause of the chronic fatigue.

Thus, there is considerable evidence of abnormalities in the CNS, particularly the limbic system, in patients with CFS. The aetiology of the abnormalities, and their relationship to the symptoms of CFS, remains obscure. One interesting hypothesis that links infection with central nervous system dysfunction is the possibility of a chronic viral encephalitis as an initiator of a process leading to CFS. It is known that viruses in animals [120121] and humans [122–125] can affect the HPA-axis, thus making infectious agents that cause CNS disturbances of particular interest. Dysfunction of the hypothalamus could explain many of the symptoms of CFS.

Influence of stress

  1. Top of page
  2. Abstract
  3. Historical background and origins
  4. Clinical picture and epidemiology
  5. CFS and psychiatric disorders
  6. Is CFS a post-infectious condition?
  7. Immunological findings
  8. Influence of stress
  9. Conclusion
  10. References

The influence of stress, in conjunction with infection, also was introduced early on as a possible cause [126]. The pace of ‘modern’ society was blamed [127] and still is [3]. The patients themselves often believe that a virus together with stress were the causative agents [128].

The involvement of stress in the pathogenesis of this illness seems clear for most physicians, and many patients acknowledge the influence of this factor on the natural course of symptoms. Stress can be divided into long-term and short-term subgroups which have different effects on human physiology. There is also the influence of biological adaptation. At low levels, stress may actually improve some aspects of immune function [129]. However, most types of stress have been shown to impair immune system function and, in general, the immune defence against viral illness [130]. One example is herpes simplex which rests, latent, in the neurones, but is susceptible to reactivation by a variety of factors including immune suppression, fever, hormonal changes, and physical and emotional stress.

Perhaps the best studied activation system in the body is the hypothalamus–pituitary–adrenocortical (HPA) axis. This system is an example of a negative feedback circuit. Corticotropin-releasing hormone (CRH) released from the hypothalamus stimulates the pituitary gland to secrete adrenocorticotropin hormone (ACTH), which in turn stimulates the adrenal cortex to secrete cortisol into the blood. An increase in the concentration of cortisol in the blood results in a direct inhibition of CRH secretion by the hypothalamus.

Under chronic stress, different disturbances in this feedback can occur. In conditions of deep depression, the whole HPA axis seems to be hyperactive, where cortisol does not inhibit the secretion of CRH in the normal way [131132]. In post-traumatic stress disorder the basal secretion of cortisol is low, but when the individual is reminded of the horrible events he/she experienced, the axis is immediately awakened [133]. In CFS it seems, instead, that the CRH activity has become attenuated. As CRH is the impetus, the activity of the whole axis is generally low [30]. So far no one has been able to determine the mechanisms behind these three types of disturbances, but research in animals and humans has confirmed these abnormal patterns of function [30103134–141].

However, basal activity of the HPA axis in CFS patients has not been found to differ from controls by some authors [142].

A dysregulation of the HPA axis was found in patients with fibromyalgia, a condition sharing some characteristics with CFS. These patients also have increased levels of the neuropeptide substance P in cerebrospinal fluid which, however, was detected within normal range in CFS patients [143], thus making it a potential biological differential marker.

Recent data also present the possibility that there are abnormalities in the GH-IGF axis in CFS patients [144]. Whether this is caused by a primary pathological process is not known. It is important to further clarify the observed variations in the relevant endocrinological parameters.

As an example of the effects of a single stress factor, the effects of Hurricane Andrew were studied in CFS patients in Florida [145]. It was found that patients from the high impact area had significant increases in physician-related clinical relapses and an exacerbation in frequency of several categories of self-reported physical symptoms compared to patients from lower impact areas. Illness burden also was significantly increased. The patients’ post-hurricane distress response was the single strongest predictor of the probability and severity of relapse and functional impairment. Optimism and social support were significantly associated with lower illness burden after the hurricane.

We know that there is a common chemical language, only partly deciphered, for the brain, immune, and endocrine systems [146]. The immune and neuroendocrine systems represent a totally integrated information circuit, a result of sharing ligands and their receptors. The immune system communicates with the neuroendocrine system and can, at a local level, itself act as an effective endocrine organ. It is probable that small perturbations in immunological stimuli may cause major fluctuations in endocrine status [147].

Treatment

Studies of different treatment schemes are not easy to perform in this condition. This is probably a consequence of the heterogeneity of patient populations and complexity of origin. Therefore, data have to be analysed comparing different groups of patients (e.g. those with gradual versus sudden onset, symptom severity, etc.) and control groups are needed. The use of a common case definition in defining subjects of all treatment studies should help this problem, but not eliminate it: most investigators believe that the cases circumscribed by the current CDC case definition are probably still a heterogeneous group. The hope is that application of the case definition will reduce heterogeneity, although it probably will not eliminate it. As the definition of CFS becomes more accepted and used by international research groups, comparable studies should become easier to perform. The natural course of CFS is still largely unknown and the cyclic nature of the symptoms presents problems when treatments are being evaluated. Also, the absence of objective markers of this illness makes evaluation more difficult and dependent on subjective measurements. Thus, studies are not easy to design and evaluate.

Relatively few large randomized trials of therapy have been conducted. Many clinicians report, from uncontrolled experience, that low doses of tricyclic agents seem to help patients – particularly in alleviating the sleep problems. This is of interest because of the proven value of low-dose tricyclics in a very similar syndrome, fibromyalgia [148149]. Patients usually have difficulty tolerating doses used for treatment of depression, as sedative and anticholinergic effects cause disturbing side-effects. Therefore, other classes of antidepressant drugs have been tried. Selective serotonin reuptake antagonists (SSRA) should, theoretically, be beneficial, as serotonergic pathways also play a role in sleep disturbances and sympathetic drive. A double-blinded study using fluoxetine (Prozac), however, showed no effect [150]. One small study of a monoamine oxidase inhibitor (phenelzine) showed some improvement of symptoms [151]. In practice, many patients are reluctant to take these drugs.

The antiviral medication, acyclovir, was found ineffective [152]; however, this medication has minimal or no in vitro activity against the viruses that have most frequently been associated with CFS. In a large randomized trial, the immune modulating drug, Ampligen, was found to have an effect on both symptoms and objective parameters over a 26-week period, but there was no evaluation of the durability of the improvement following the end of therapy [153]. Amantadine [154] has also been tried, not because of its antiviral properties, but because of its central effects in releasing noradrenaline and dopamine, retarding reuptake of these transmitters, and its demonstrated value in improving the fatigue seen in some patients with multiple sclerosis. None have proven efficient in relieving CFS symptoms.

Other drugs studied include the oral antihistamine terfenadine [155] and alpha-interferon [156]. Neither showed any therapeutic effect in CFS patients. Carnitine, essential for mitochondrial energy production, has been found to be beneficial to the patients in one study [154]. Immunologic therapy with high dosages of gammaglobulin given intravenously have not been found to be effective [157158]. Low-dose hydrocortisone was associated with some improvement in symptoms but the degree of adrenal suppression precludes its practical use for CFS [159].

Cognitive behavioural therapy has been used in different schemes – either in groups [160161] or, more successfully, on an individual basis [162]. The latter form proved effective in moderating symptoms, at one-year follow-up. Cognitive behaviour therapy emphasizes self-help. The goal is to help the patient to change unhelpful cognitions and behaviour. Although the effect has rarely so far been shown to be curative, the effect is substantial. At present, intensive individual CBT administered by trained staff is one treatment of choice [163].

Clinical management of conditions such as CFS is not developed at all levels of the health care system. This causes problems for many clinicians coming into contact with this illness for the first time, as information regarding diagnosis and treatment is not readily available [164]. Updated information on CFS and distribution of such to clinicians is important and needed.

Trust must be established between the patient and doctor, as a thorough clinical investigation, to exclude other probable illness causes, is of utmost importance. A complete detailed life history must include both physical and psychological problems, which often require the expertise of a specialist to exclude them.

If the diagnosis of CFS is established, information on current knowledge should be given to the patient and repeated. This includes possible triggering events (e.g. infections in a predisposed individual), and factors that can perpetuate the condition. Cognitive behavioural therapy should be used on an individual basis if possible. A consistent pattern of living – including work, rest, sleep, and physical activity – should be applied, and a slow increase of daily activities introduced. It should be explained that even a slow increase in physical exercise can cause an exacerbation of symptoms, but often these subside with time and there is improvement.

Prognosis

Since an internationally accepted case definition was established in 1994, few follow-up studies have been performed on patients meeting this criterion. However, a systematic review of these studies indicates that less than 10% of patients recover completely [165]. Risk factors for poor prognosis appear to be older age, comorbid disorders, and holding to the belief that the illness is due to physical causes.

Conclusion

  1. Top of page
  2. Abstract
  3. Historical background and origins
  4. Clinical picture and epidemiology
  5. CFS and psychiatric disorders
  6. Is CFS a post-infectious condition?
  7. Immunological findings
  8. Influence of stress
  9. Conclusion
  10. References

Chronic fatigue syndrome (CFS) is an illness that produces physical symptoms and, in some individuals, psychological morbidity. Although a large number of objective, biological abnormalities have been identified in the patients, no diagnostic test with adequate sensitivity and specificity is yet available. Moreover, the pathogenesis of the illness has not been completely delineated. When this is the state of affairs in understanding an illness, as it has been and is with many, observers have varying opinions about the illness, and controversy is generated.

This controversy is exaggerated by the mind–body dualism that still is present in Western thinking. Plato introduced, and Decartes reinforced, the concept of a dichotomy between body and soul, and of illnesses of the body versus illnesses of the soul. Moreover, illnesses of the body are often viewed as ‘real’, whereas diseases of the soul are not. Until an illness becomes a disease, with a clear pathogenesis and diagnostic markers, it is not taken seriously by some clinicians.

This separation often leads to failure in the care given to individuals experiencing ill health due to an illness, and it is mainly due to this philosophy laying the foundation for our medical education. With new techniques being developed, our capacity to investigate underlying biological causes of ill health is increasing, independent of the psychological or physical origins of the symptoms.

CFS can be viewed as a model of ill health in which biological disturbances lead to symptoms which our culture considers either psychosomatic or imaginative. Current research points to an intimate contact between the immune system and the central nervous system, with the possible involvement of a microorganism causing disturbances in systems affecting the function of the individual. The origin is bound to be complex, and it may well be that the solution will come together with a more generally altered view about mind–body dualism, and the concept of illness and disease.

References

  1. Top of page
  2. Abstract
  3. Historical background and origins
  4. Clinical picture and epidemiology
  5. CFS and psychiatric disorders
  6. Is CFS a post-infectious condition?
  7. Immunological findings
  8. Influence of stress
  9. Conclusion
  10. References
  • 1
    Straus SE. History of chronic fatigue syndrome. Rev Infect Dis 1991; 13(Suppl.): 2 7.
  • 2
    Beard G. Neurasthenia, or nervous exhaustion. Boston Med Surg J 1869; 80: 217 20.
  • 3
    Johannisson K. Medicinens öga. Norstedts förlag. Stockholm: 1990.
  • 4
    Wessely S. Old wine in new bottles: neurasthenia and ‘ME’. Psychol Med 1990; 20: 35 53.
  • 5
    Freund JD. Psychoanalysis-uses and abuses. Psychosomatics 1972; 6: 377 9.
  • 6
    Ramsay AM & O’Sullivan E. Encephalomyelitis stimulating poliomyelitis. Lancet 1956; 1: 761 4.
  • 7
    Richardson AT. Some aspects of the Royal Free Hospital epidemic. Ann Phys Med 1956; 3: 81 9.
  • 8
    McEvedy CP & Beard AW. Royal Free epidemic of 1955: a reconsideration. Br Med J 1970; 1: 7 11.
  • 9
    Wessely S & Powell R. Fatigue syndromes: a comparison of chronic ‘postviral’ fatigue with neuromuscular and affective disorders. J Neurol Neurosurg Psychiatry 1989; 52: 940 48.
  • 10
    Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121: 953 9.
  • 11
    Wessely S. The epidemiology of chronic fatigue syndrome. Epidemiol Rev 1995; 17: 139 51.
  • 12
    Hagnell O, Grasbeck A, Ojesjo L, Otterbeck L. Mental tiredness in the Lundby study. Incidence and course over 25 years. Acta Psychiatr Scand 1993; 88: 316 21.
  • 13
    Kroenke K, Arrington ME, Mangelsdorff AD. The prevalence of symptoms in medical outpatients and the adequacy of therapy. Arch Intern Med 1990; 150: 1685 9.
  • 14
    Bates DW, Schmitt W, Buchwald D, Ware N, Lee J, Thoyer E. Prevalence of fatigue and chronic fatigue syndrome in a primary care practice. Arch Intern Med 1993; 153: 2759 65.
  • 15
    Komaroff AL. ‘Minor’ illness symptoms: the magnitude of their burden and of our ignorance. Arch Intern Med 1990; 150: 1586 7.
  • 16
    Cox B, Blaxter M, Buckle J. The Health and Lifestyle Survey. London: Health Promotion Research Trust, 1987.
  • 17
    Buchwald D, Umali P, Umali J, Kith P, Pearlman T, Komaroff AL. Chronic fatigue and the chronic fatigue syndrome: prevalence in a Pacific Northwest heath care system. Ann Intern Med 1995; 123: 81 8.
  • 18
    Wessely S, Chalder T, Hirsch S, Wallace P, Wright D. The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: a prospective primary care study. Am J Publications Health 1997; 9: 1449 55.
  • 19
    Buchwald D & Garrity D. Comparisons of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. Arch Intern Med 1994; 154: 2049 53.
  • 20
    Nisenbaum R, Reyes M, Mawle AC, Reeves WC. Factor analysis of unexplained severe fatigtue and interrelated symptoms. Overlap with criteria for chronic fatigue syndrome. Am J Epidemiol 1998; 148: 72 7.
  • 21
    Komaroff AL, Fagioli LR, Doolittle TH, et al. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med 1996; 101: 281 90.
  • 22
    Buchwald D, Pearlman T, Kith P, Schmaling K. Gender differences in patients with chronic fatigue syndrome. J Gen Intern Med 1994; 9: 397 401.
  • 23
    Centers for Disease Control and Prevention. Chronic Fatigue Syndrome Research Program. Presented, U.S. Department of Health and Human Services, 1995.
  • 24
    Taerk GS, Toner BB, Salit IE, Garfinkel PE, Ozersky S. Depression in patients with neuromyasthenia [benign myalgic encephalomyelitis]. Int J Psychiatry Med 1987; 17: 49 56.
  • 25
    Hickie I, Lloyd A, Wakefield D, Parker G. The psychiatric status of patients with the chronic fatigue syndrome. Br J Psychiatry 1990; 156: 534 40.
  • 26
    Kruesi Mjp, Dale J, Straus SE. Psychiatric diagnoses in patients who have chronic fatigue syndrome. J Clin Psychiatry 1989; 50: 53 6.
  • 27
    Katon WJ, Buchwald DS, Simon GE, Russo JE, Mease PJ. Psychiatric illness in patients with chronic fatigue and those with rheumatoid arthritis. J Gen Intern Med 1991; 6: 277 85.
  • 28
    Pepper CM, Krupp LB, Friedberg F, Doscher C, Coyle PK. A comparison of neuropsychiatric characteristics in chronic fatigue syndrome, multiple sclerosis, and major depression. J Neuropsychiatry Clin Neurosci 1993; 5: 200 205.
  • 29
    Powell R, Dolan R, Wessely S. Attributions of self-esteem in depression and chronic fatigue syndromes. J Psychosom Res 1990; 34: 665 73.
  • 30
    Demitrack MA, Dale JK, Straus SE, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991; 73: 1224 34.
  • 31
    Sharpe M, Clements A, Hawton K, Young AH, Sargent P, Cowen PJ. Increased prolactin response to buspirone in chronic fatigue syndrome. J Affect Disord 1996; 41: 71 6.
  • 32
    Bakheit Amo, Behan PO, Dinan TG, Gray CE, O’Keane V. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. Br Med J 1992; 304: 1010 12.
  • 33
    Dinan TG. Neuroendocrinology of chronic fatigue syndrome. J Chronic Fatigue Syndrome 1996; 2: 69 70.
  • 34
    Schwartz RB, Komaroff AL, Garada BM, et al. SPECT imaging of the brain: comparison of findings in patients with chronic fatigue syndrome, AIDS dementia complex, and major unipolar depression. Am J Roentgenol 1994; 162: 943 51.
  • 35
    Kraepelin E. Clinical Psychiatry (transl. DefendorfR). London: Macmillan, 1902.
  • 36
    Dutil A. Neurasthénie in Traité de Pathologie Mentale (BalletG, ed.). Paris: Octave Doin, 1903;842 50.
  • 37
    Savill T. & Henry J, ed. Clinical Lectures on Neurasthenia. London: Glaisher, 1906.
  • 38
    Oppenheim H. Text-Book of Nervous Diseases for Physicians and Students, Vol II, 5th edn (transl BruceA). London: Fouli, 1911.
  • 39
    Sigal LH. Summary of the first 100 patients seen at a Lyme disease referral center. Am J Med 1990; 88: 577 81.
  • 40
    Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. JAMA 1993; 269: 1812 16.
  • 41
    Coyle PK, Krupp LB, Doscher C, Amin K. Borrelia burgdorfen reactivity in patients with severe persistent fatigue who are from a region in which Lyme disease is endemic. Clin Infect Dis 1994; 18: S24 7.
  • 42
    Marmion BP, Shannon M, Maddocks I, Storm P, Penttila I. Protracted debility and fatigue after acute Q fever. Lancet 1996; 347: 977 8.
  • 43
    Lloyd AR, Wakefield D, Hickie I. Immunity and the pathophysiology of chronic fatigue syndrome. In: BockGR, WhelanJ, eds. Ciba Foundation Symposium 173, Chronic Fatigue Syndrome. New York: J. Wiley & Sons, 1993: 176 92.
  • 44
    Acheson ED. The clinical syndrome variously called benign myalgic encephalomyelitis, Iceland disease and epidemic neuromyasthenia. Am J Med 1959; 26: 569 95.
  • 45
    Henderson DA & Shelokov A. Epidemic neuromyasthenia –clinical syndrome? N Engl J Med 1959; 260: 757 64,814 18.
  • 46
    Gilliam AG. Epidemiologic study on an epidemic, diagnosed as poliomyelitis, occurring among the personnel of Los Angeles County General Hospital during the summer of 1934. Publications Health Bull 1938; 240: 1 90. Washington DC Public Health Service
  • 47
    Holmes GP, Kaplan JE, Stewart JA, Hunt B, Pinsky PF, Schonberger LB. A cluster of patients with a chronic mononucleosis–like syndrome. Is Epstein-Barr virus the cause? JAMA 1987; 257: 2297 302.
  • 48
    Daugherty SA, Henry BE, Peterson DL, Swarts RL, Bastien S, Thomas RS. Chronic fatigue syndrome in northern Nevada. Rev Infect Dis 1991; 13 Suppl.]: S39 S44.
  • 49
    Buchwald D, Cheney PR, Peterson DL, et al. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med 1992; 116: 103 13.
  • 50
    Straus SE, Tosato G, Armstrong G, et al. Persisting illness and fatigue in adults with evidence of Epstein–Barr virus infection. Ann Intern Med 1985; 102: 7 16.
  • 51
    Jones JF, Ray CG, Minnich LL, Hicks MJ, Kibler R, Lucas DO. Evidence for active Epstein-Barr virus infection in patients with persistent unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med 1985; 102: 1 7.
  • 52
    Yalcin S, Kuratsune H, Yamaguchi K, Kitani T, Yamanishi K. Prevalence of human herpesvirus 6 variants A and B in patients with chronic fatigue syndrome. Microbiol Immunol 1994; 38: 587 90.
  • 53
    Patnaik M, Komaroff AL, Conley E, Ojo-Amaize EA, Peter JB. Prevalence of IgM antibodies to human herpesvirus 6 early antigen [p41/38] in patients with chronic fatigue syndrome. J Infect Dis 1995; 172: 1364 7.
  • 54
    Zorzenon M, Rukh G, Botta GA, Colle R, Barsanti LA, Ceccherini-Nelli L. Active HHV-6 infection in chronic fatigue syndrome patients from Italy: new data. J Chronic Fatigue Syndrome 1996; 2: 3 12.
  • 55
    Carrigan DR, Harrington DP, Knox KK. Subacute leukoencephalitis caused by CNS infection with human herpesvirus-6 manifesting as multiple sclerosis. Neurol 1996; 47: 145 8.
  • 56
    Caserta MT, Hall CB, Schnabel K, et al. Neuroinvasion and persistence of human herpesvirus-6 in children. J Infect Dis 1994; 170: 1586 9.
  • 57
    Challoner PB, Smith KT, Parker JD, et al. Plaque associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA 1995; 92: 7440 44.
  • 58
    DeFreitas E, Hilliard B, Cheney PR, Bell DS, Kiggundu E, Sankey D. Retroviral sequences related to human T-lymphotropic virus type II in patients with chronic fatigue immune dysfunction syndrome. Proc Natl Acad Sci USA 1991; 88: 2922 6.
  • 59
    Khan AS, Heneine WM, Chapman LE, et al. Assessment of a retrovirus sequence and other possible risk factors for the chronic fatigue syndrome. Ann Intern Med 1993; 118: 241 5.
  • 60
    Behan PO, Behan Wmh, Bell EJ. The postviral fatigue syndrome: an analysis of the findings in 50 cases. J Infect 1985; 10: 211 22.
  • 61
    Archard LC, Bowles NE, Behan PO, Bell EJ, Doyle D. Postviral fatigue syndrome: persistence of enteroviral RNA in muscle and elevated creatine kinase. J Soc Med 1988; 81: 326 9.
  • 62
    Yousef GE, Mann GF, Smith DG, Bell EJ, McCartney RA. Chronic enterovirus infection in patients with postviral fatigue syndrome. Lancet 1988; 1: 146 50.
  • 63
    Gow JW, Behan Wmh, Clements GB, Woodall C, Riding M, Behan PO. Enteroviral RNA sequences detected by polymerase chain reaction in muscle of patients with postviral fatigue syndrome. Br Med J 1991; 302: 692 6.
  • 64
    Lindh G, Samuelsson A, Hedlund KO, Evengard B, Lindquist L, Ehrnst A. No findings of enteroviruses in Swedish patients with chronic fatigue syndrome. Scand J Infect Dis 1996; 28: 305 7.
  • 65
    Swanink Cma, Melchers Wjg, Van deer Meer Jwm, Vercoulen JH, Bleijenberg G, Fennis JF, et al. Enteroviruses and the chronic fatigue syndrome. Clin Infect Dis 1994; 19: 860 64.
  • 66
    McArdle A, McArdle F, Jackson MJ, Page SF, Fahal I, Edwards RH. Investigation by polymerase chain reaction of enteroviral infection in patients with chronic fatigue syndrome. Clin Sci 1996; 90: 295 300.
  • 67
    Ludwig H, Bode L, Gosztonyi G. Borna disease: a persistent virus infection of the central nervous sytem. Prog Med Virol 1988; 35: 107 51.
  • 68
    Briese T, De La Torre JC, Lewis A, Ludwig H, Lipkin WI. Borna disease virus, a negative-strand RNA virus, transcribes in the nucleus of infected cells Proc Natl Acad Sci, USA 1992; 89: 11486 9.
  • 69
    Nakaya T, Takahashi H, Nakamura Y, et al. Demonstration of Borna disease virus RNA in peripheral blood mononuclear cells derived from Japanese patients with chronic fatigue syndrome. FEBS Lett 1996; 378: 145 9.
  • 70
    Kitani T, Kuratsune H, Fuke I, et al. Possible correlation between Borna disease virus infection and Japanese patients with chronic fatigue syndrome. Microbiol Immunol 1996; 40: 459 62.
  •  70a 
    Evergård B, Lindh G, Lipkin WI, Lee S. No evidence of Borna disease virus in patients with chronic fatigue syndrome. J Neurovirology : (in press).
  • 71
    Suhaldonik RJ, Reichenbach NL, Hitzges P, et al. Upregulation of the 2–5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 1994; 18(Suppl. 1): S96 104.
  • 72
    Suhaldonik RJ, Peterson DL, O’Brien K, et al. Biochemical evidence for a novel low molecular weight 2–5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res 1997; 17: 377 85.
  • 73
    Bates DW, Buchwald D, Lee J, et al. Clinical laboratory test findings in patients with chronic fatigue syndrome. Arch Intern Med 1995; 155: 97 103.
  • 74
    Landay AL, Jessop C, Lennette ET, Levy JA. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991; 338: 707 12.
  • 75
    Straus SE, Fritz S, Dale JK, Gould B, Strober W. Lymphocyte phenotype and function in the chronic fatigue syndrome. J Clin Immunol 1993; 13: 30 40.
  • 76
    Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990; 28: 1403 10.
  • 77
    Tirelli U, Pinto A, Marotta G, et al. Clinical and immunologic study of 205 patients with chronic fatigue syndrome: a case series from Italy. Arch Intern Med 1993; 153: 116 17.
  • 78
    Aoki T, Usuda Y, Miyakoshi H, Tamura K, Herberman RB. Low natural killer syndrome: clinical and immunologic features. Nat Immun Cell Growth Regul 1987; 6: 116 28.
  • 79
    Caligiuri M, Murray C, Buchwald D, et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol 1987; 139: 3306 13.
  • 80
    Eby NL, Grufferman S, Huang M, et al. Natural killer cell activity in the chronic fatigue–immune dysfunction syndrome. In: AdesEW, LopezC, eds. Natural Killer Cells and Host Defense. Basel : Karger, 1989; 141 5.
  • 81
    Morrison Lja, Behan Wmh, Behan PO. Changes in natural killer cell phenotype in patients with post–viral fatigue syndrome. Clin Exp Immunol 1991; 83: 441 6.
  • 82
    Grufferman S, Levine PH, Eby NL, et al. Results of an investigation of three clusters of chronic fatigue syndrome. Clin Infect Dis 1994; 18(Suppl.1): S55 6.
  • 83
    Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis 1994; 18(Suppl. 1): S157 9.
  • 84
    Gupta S & Vayuvegula B. A comprehensive immunological analysis in chronic fatigue syndrome. Scand J Immunol 1991; 3: 319 27.
  • 85
    Lloyd A, Hickie I, Hickie C, Dwyer J, Wakefield D. Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression. Clin Exp Immunol 1992; 87: 76 9.
  • 86
    Konstantinov K, Von Mikecz A, Buchwald D, Jones J, Gerace L, Tan EM. Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. J Clin Invest 1996; 98: 1888 96.
  • 87
    Peakman M, Deale A, Field R, Mahalingam M, Wessely S. Clinical improvement in chronic fatigue syndrome is not associated with lymphocyte subsets of function or activation. Clin Immunol Immunopathol 1997; 82: 83 91.
  • 88
    Bennett AL, Chao CC, Hu S, et al. Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome. J Clin Immunol 1997; 17: 160 66.
  • 89
    Chao CC, Gallagher M, Phair J, Peterson PK. Serum neopterin and interleukin-6 levels in chronic fatigue syndrome. J Infect Dis 1990; 162: 1412 13.
  • 90
    Linde A, Andersson B, Svenson SB, et al. Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis 1992; 165: 994 1000.
  • 91
    Chao CC, Janoff EN, Hu SX, et al. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine 1991; 3: 292 8.
  • 92
    Gupta S, Aggarwal S, See D, Starr A. Cytokine production by adherent and non-adherent mononuclear cells in chronic fatigue syndrome. J Psychiatr Res 1997; 31: 149 56.
  • 93
    Cannon JG, Angel JB, Abad LW, et al. Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. J Clin Immunol 1997; 17: 253 61.
  • 94
    Edwards RH, Gibson H, Clague JE, Helliwell T. Muscle histopathology and physiology in chronic fatigue syndrome. In: BockGR, WhelanJ, eds. Chronic Fatigue Syndrome Chichester : John Wiley & Sons, 1993; 102 31.
  • 95
    Gibson H, Carroll N, Clague JE, Edwards RH. Exercise performance and fatiguability in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry 1993; 56: 993 8.
  • 96
    Lloyd AR, Hales JR, Gandevia SC. Muscle strength, endurance and recovery in the post–infection fatigue syndrome. J Neurol Neurosurg Psychiatry 1988; 51: 1316 22.
  • 97
    Natelson BH, Cohen JM, Brassloff I, Lee H-J. A controlled study of brain magnetic resonance imaging in patients with the chronic fatigue syndrome. J Neurol Sci 1993; 120: 213 17.
  • 98
    Ichise M, Salit IE, Abbey SE, et al. Assessment of regional cerebral perfusion by 99Tcm-HMPAO SPECT in chronic fatigue syndrome. Nucl Med Commun 1992; 13: 767 72.
  • 99
    Costa DC, Tannock C, Brostoff J. Brainstem perfusion is impaired in chronic fatigue syndrome. Q J Med 1995; 88: 767 73.
  • 100
    Cope H & David AS. Neuroimaging in chronic fatigue syndrome. J Neurol Neurosurg Psychiatry 1996; 60: 471 3.
  • 101
    Bou-Holaigah I, Rowe PC, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 1995; 274: 961 7.
  • 102
    Freeman R & Komaroff AL. Does the chronic fatigue syndrome involve the autonomic nervous system? Am J Med 1997; 102: 357 64.
  • 103
    Demitrack MA, Gold PW, Dale JK, Krahn DD, Kling MA, Straus SE. Plasma and cerebrospinal fluid monamine metabolism in patients with chronic fatigue syndrome: preliminary findings. Biol Psychiatry 1992; 32: 1065 77.
  • 104
    Cleare AJ, Bearn J, Allain T, et al. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord 1995; 35: 283 9.
  • 105
    Furman JmR. Testing of vestibular function: an adjunct in the assessment of chronic fatigue syndrome. Rev Infect Dis 1991; 13(Suppl. 1): S109 11.
  • 106
    Ash-Bernal R, Wall C III, Komaroff AL, et al. Vestibular function test anomalies in patients with chronic fatigue syndrome. Acta Otolaryngol 1995; 115: 9 17.
  • 107
    Abbey SE & Garfinkel PE. Chronic fatigue syndrome and depression: cause, effect, or covariate. Rev Infect Dis 1991; 13(Suppl.): 73 83.
  • 108
    Komaroff AL. Post–viral fatigue syndrome: a review of American research and practice. In: JenkinsR, MowbrayJ, eds. Post–Viral Fatigue Syndrome. West Sussex, UK: John Wiley & Sons, 1991;41 59.
  • 109
    Grafman J, Johnson R Jr, Scheffers M. Cognitive and mood-state changes in patients with chronic fatigue syndrome. Rev Infect Dis 1991 ; ( Suppl. 1): 45 52.
  • 110
    Johnson SK, DeLuca J, Fiedler N, Natelson BH. Cognitive functioning of patients with chronic fatigue syndrome. Clin Infect Dis 1994; 18(Suppl. 1): S84 5.
  • 111
    Marcel B, Komaroff AL, Fagioli LR, Kornish RJ, Albert MS. Cognitive deficits in patients with chronic fatigue syndrome. Biol Psychiatry 1996; 40: 535 41.
  • 112
    Michiels V, Cluydts R, Fischler B, Hoffmann G, Le Bon O, De Meirleir K. Cognitive functioning in patients with chronic fatigue syndrome. J Clin Exp Neuropsychol 1996; 18: 666 77.
  • 113
    DeLuca J, Johnson SK, Beldowicz D, Natelson BH. Neuropsychological impairments in chronic fatigue syndrome, multiple sclerosis, and depression. J Neurol Neurosurg Psychiatry 1995; 58: 38 43.
  • 114
    DeLuca J, Johnson SK, Ellis SP, Natelson BH. Cognitive functioning is impaired in patients with chronic fatigue syndrome devoid of psychiatric disease. J Neurol Neurosurg Psychiatry 1997; 62: 151 5.
  • 115
    DeLuca J, Johnson SK, Ellis SP, Natelson BH. Sudden vs gradual onset of chronic fatigue syndrome differentiates individuals on cognitive and psychiatric measures. J Psychiatr Res 1997; 31: 83 90.
  • 116
    Tiersky LA, Johnson SK, Lange G, Natelson BH, DeLuca J. Neuropsychology of chronic fatigue syndrome: a critical review. J Clin Exp Neuropsychol 1997; 19: 560 86.
  • 117
    Moldofsky H. Fibromyalgia, sleep disorder, and chronic fatigue syndrome. In: BockGR, WhelanJ, eds. Chronic Fatigue Syndrome, Ciba Found Symp, New York: John Wiley & Sons, 1993 : 262 71.
  • 118
    Krupp LB, Jandorf L, Coyle PK, Mendelson WB. Sleep disturbance in chronic fatigue syndrome. J Psychosom Res 1993; 37: 325 31.
  • 119
    Buchwald D, Pascualy R, Bombardier C, Kith P. Sleep disorders in patients with chronic fatigue. Clin Infect Dis 1994; 18(Suppl. 1): S68 72.
  • 120
    Oldstone MB, Holmstoen J, Welsh Rm Jr. Alterations of acetylcholine enzymes in neuroblastoma cells persistently infected with lymphocytic choriomeningitis virus. J Cell Physiol 1977; 91: 459 72.
  • 121
    Oldstone MB, Sinha YN, Blount P, et al. Virus-induced alterations in homeostasis: alterations in differentiated functions of infected cells in vivo. Science 1982; 218: 1125 7.
  • 122
    Preeyasombat C, Richards C, Silverman M, Kenny FM. Cortisol production. III. Rubella and varicella encephalopathy, with a note on their treatment with steroids. Am J Dis Child 1965; 110: 370 73.
  • 123
    White MG, Carter NW, Rector FC, et al. Pathophysiology of epidemic St. Louis encephalitis. I. Inappropriate secretion of antidiuretic hormone. II. Pituitary-adrenal function. III. Cerebral blood flow and metabolism. Ann Intern Med 1969; 71: 691 702.
  • 124
    Zeitoun MM, Hassan AI, Hussein ZM, Fahmy MS, Ragab M, Hussein M. Adrenal glucocorticoid function in acute viral infections in children. Acta Paediatr Scand 1973; 62: 608 14.
  • 125
    Merenich JA, McDermott MT, Asp AA, Harrison SM, Kidd GS. Evidence of endocrine involvement early in the course of human immunodeficiency virus infection. J Clin Endocrinol Metab 1990; 3: 566 71.
  • 126
    Lane C. The mental element in the etiology of neurasthenia. J Nervous Mental Dis 1906; 33: 463 6.
  • 127
    Beard G. American Nervousness. New York: GP Putnam, 1881.
  • 128
    Chalder T, Power MJ, Wessely S. Chronic fatigue in the community: ‘a question of attribution. Psychol Med 1996; 26: 791 800.
  • 129
    Esterling BA, Antoni MH, Schneiderman N, et al. Psychosocial modulation of antibody to Epstein–Barr viral capsid antigen and human herpesvirus type-6 in HIV-1 infected and at-risk gay men. Psychosom Med 1992; 54: 354 71.
  • 130
    Cohen S, Tyrrell DA, Smith AP. Psychological stress and susceptibility to the common cold. N Engl J Med 1991; 325(9): 606 12.
  • 131
    Gold PW, Chrousos GP, Kellner C, Post R, Augerinos P, Schulte H. Psychiatric implications of basic and clinical studies with corticotropin releasing hormone. Am J Psychiatry 1984; 141: 619 27.
  • 132
    Roy A, Pickar D, Paul SM, Doran A, Chrousos GP, Gold PW. CSF corticotropin releasing hormone in depressed patients and normal control subjects. Am J Psychiatry 1987; 144: 641 5.
  • 133
    Yehuda R, Giller EL, Southwick SM, Lowy MT, Mason JW. Hypothalamic-pituitary-adrenal dysfunction in post-traumatic stress disorder. Biol Psychiatry 1991; 30: 1031 48.
  • 134
    Michelson d Gold PW & Sternberg EM. The stress response in critical illness. New Horiz 1994; 2: 426 31.
  • 135
    Michelson D & Gold PW. Pathophysiologic and somatic investigations of hypothalamic-pituitary-adrenal axis activation in patients with depression. Ann N Y Acad Sci 1998; 840: 717 22.
  • 136
    Licinio J, Gold PW, Wong ML. A molecular mechanism for stress-induced alterations in susceptibility to disease. Lancet 1995; 346: 104 6.
  • 137
    Gold PW, Licinio J, Wong ML, Chrousos GP. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann N Y Acad Sci 1995; 771: 716 29.
  • 138
    Demitrack M. Chronic fatigue syndrome: a disease of the hypothalamic-pituitary-adrenal axis? Ann Med 1994; 26: 1 5.
  • 139
    Demitrack MA & Crofford LJ. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann N Y Acad Sci 1998; 840: 684 97.
  • 140
    Scott LV & Dinan TG. Urinary free cortisol excretion in chronic fatigue syndrome, major depression and in healthy volunteers. J Affect Disord 1998; 47: 49 54.
  • 141
    Scott LV, Medbak S, Dinan TG. Blunted adrenocorticotropin and cortisol responses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome. Acta Psychiatr Scand 1998; 97: 450 57.
  • 142
    Young AH, Sharpe M, Clements A, Dowling B, Hawton KE, Cowen PJ. Basal activity of the hypothalamic-pituitary-adrenal axis in patients with the chronic fatigue syndrome [neurasthenia]. Biol Psychiatry 1998; 43: 236 7.
  • 143
    Evengård B, Nilsson CG, Lindh G et al. No evidence for elevated substance P levels in cerebrospinal fluid of patients with CFS. Pain 1998; 78: 153 155.
  • 144
    Allain TJ, Bearn JA, Coskeran P, et al. Changes in growth hormone, insulin, insulin-like growth factors [IGFs], and IGF-binding protein-1 in chronic fatigue syndrome. Biol Psychiatry 1997; 41: 567 73.
  • 145
    Lutgendorf SK, Antoni MH, Ironson G, et al. Physical symptoms of chronic fatigue syndrome are exacerbated by the stress of hurricane Andrew. Psychosom Med 1995; 57: 310 23.
  • 146
    Blalock JE. The syntax of immune-neuroendocrine communication. Immunol Today 1994; 15: 504 11.
  • 147
    Grossman A & Costa A. The regulation of hypothalamic CRH: impact of in vitro studies on the central control of the stress response. Funct Neurol 1993; 8: 325 34.
  • 148
    Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986; 29: 1371 7.
  • 149
    Carette S, Bell MJ, Reynolds WJ. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. Arthritis Rheum 1994; 1: 32.
  • 150
    Vercoulen Jhmm, Swanink Cma, Zitman FG, et al. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996; 347: 858 61.
  • 151
    Natelson BH, Cheu J, Pareja J, Ellis SP, Policastro T, Findley TW. Randomized, double blind, controlled placebo-phase in trial of low dose phenelzine in chronic fatigue syndrome. Psychopharmacology (Berl ) 1996; 124: 226 30.
  • 152
    Straus SE, Dale JK, Tobi M, et al. Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial. N Engl J Med 1988; 319(26): 1692 8.
  • 153
    Strayer DR, Carter WA, Brodsky I, et al. A controlled clinical trial with a specifically configured RNA drug, poly[I]·poly[C12U], in chronic fatigue syndrome. Clin Infect Dis 1994; 18(Suppl. 1): S88 95.
  • 154
    Plioplys AV & Plioplys S. Amantadine and l-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology 1997; 35: 16 23.
  • 155
    Steinberg P, McNutt BE, Marshall P, et al. Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome. J Allergy Clin Immunol 1996; 97: 119 26.
  • 156
    See DM & Tilles JG. Alpha-interferon treatment of patients with chronic fatigue syndrome. Immunol Invest 1996; 25: 153 64.
  • 157
    Peterson PK, Shepard J, Macres M, et al. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med 1990; 89: 554 60.
  • 158
    Vollmer-Conna U, Hickie I, Hadzi-Pavlovic D, et al. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. Am J Med 1997; 103: 38 43.
  • 159
    McKenzie R, O’Fallon A, Dale J, et al. Low-dose hydrocortisone for treatment of chronic fatigue syndrome. JAMA 1998; 280: 1061 6.
  • 160
    Sharpe M. Non-pharmacological approaches to treatment. In: BockGR, WhelanJ, eds. Chronic Fatigue Syndrome, Ciba Found Symp 173. New York: John Wiley & Sons, 1993; 298 317.
  • 161
    Lloyd AR, Hickie I, Brockman A, et al. Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. Am J Med 1993; 94: 197 203.
  • 162
    Sharpe M, Hawton K, Simkin S, et al. Cognitive behaviour therapy for the chronic fatigue syndrome: a randomized controlled trial. Br Med J 1996; 312: 22 6.
  • 163
    Sharpe M. Cognitive behaviour therapy for chronic fatigue syndrome: efficacy and implications. Am J Med 1998; 105: 104 9.
  • 164
    Sharpe M, Chalder T, Palmer I, Wessely S. Chronic fatigue syndrome. A practical guide to assessment and management. Gen Hosp Psychiatry 1997; 19: 185 99.
  • 165
    Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue and chronic fatigue syndrome: a systematic review. Q J Med 1997; 90: 223 33.

Received 26 October 1998; accepted 30 November 1998.